STOCK TITAN

Imunon (IMNN) SEC Filings

IMNN NASDAQ

Imunon, Inc. filings document a Nasdaq-listed clinical-stage biotechnology issuer with common stock trading under IMNN and a business centered on non-viral DNA-mediated immunotherapy. The company's 8-K reports include financial results, business updates, clinical-program disclosures for IMNN-001 and the OVATION studies, and corporate events affecting executive roles and compensation arrangements.

Proxy and registration-related filings describe annual meeting matters, board and executive compensation governance, common-stock capital structure, and at-the-market equity offering arrangements. The filing record also includes Nasdaq listing-compliance disclosures and other public-company status reports tied to Imunon's financing, governance, and clinical-development operations.

Rhea-AI Summary

Imunon, Inc. (IMNN) is the subject of Amendment No. 3 reporting that Armistice Capital, LLC and its managing member, Steven Boyd, each beneficially own 280,508 shares of common stock, representing 4.99% of the class. Both report shared voting and dispositive power over the shares.

Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., which directly holds the shares and is entitled to dividends and sale proceeds. The statement identifies September 30, 2026, as the event date.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.56%
Tags
ownership
-
Rhea-AI Summary

Imunon, Inc. (IMNN) reported a third-quarter 2026 net loss of $3,750,287, compared with $3,429,124 a year earlier; nine-month net loss was $10,813,423, versus $10,272,178. As of September 30, 2026, cash and cash equivalents were $4,039,298 and restricted cash was $5,039,468; nine-month operating cash use was $10,213,701.

The company received $10,000,000 in its June 3, 2026 financing, with $5,000,000 held as collateral; total debt was $6,590,166 at September 30, 2026. Management said current capital is not expected to fund operations for the next 12 months if its funding and operating efforts fail, and stated these conditions raise substantial doubt about continuing as a going concern.

After quarter-end, Imunon agreed to sell ThermoDox assets to VoxelDox, contingent on VoxelDox raising at least $2.5 million. If completed, consideration includes shares equal to 4.76% of VoxelDox’s fully diluted capitalization, up to $16.5 million in milestone payments, and royalties. A proposed offering covered up to 20,000,000 common shares (or pre-funded warrants) plus warrants for up to 70,000,000 shares; its assumed maximum gross proceeds were $25.0 million. The offering remained subject to SEC effectiveness, pricing, market and closing conditions and had not closed, with no proceeds received, as of November 12, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.57%
Tags
quarterly report
-
Rhea-AI Summary

Imunon, Inc. (IMNN) reported a third-quarter 2026 net loss available to common shareholders of $3.8 million, or $0.64 per share, compared with $3.4 million, or $1.16 per share, a year earlier. Operating expenses were $3.4 million versus $3.5 million. For the first nine months of 2026, net loss available to common shareholders was $10.9 million versus $10.3 million, and operating cash used was $10.2 million, unchanged from 2025. At September 30, 2026, cash and cash equivalents were $4.0 million and restricted cash was $5.0 million.

Enrollment in the Phase 3 OVATION 3 study of IMNN-001 is expected to be completed by the first quarter of 2029. Imunon exchanged $1.2 million of outstanding debt, plus accrued and unpaid interest, for non-convertible Series B Preferred Stock; the transaction reduced the A-1 Note’s outstanding balance by approximately 43%. Imunon also agreed to sell its ThermoDox rights to VoxelDox Therapeutics, with closing contingent on VoxelDox raising $2.5 million. Consideration includes an equity stake, up to $16.5 million in development milestone payments, and significant royalties on future net sales following commercial approval.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.57%
Tags
current report
Rhea-AI Summary

Imunon, Inc. director Donald P. Braun received a grant of 11,746 common shares on November 6, 2026, at a reported price of $0.8450 per share. The shares were granted in lieu of cash for a portion of his board fees, and his direct holdings after the transaction were 33,643 shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.48%
Tags
insider
-
Rhea-AI Summary

Imunon, Inc. director James E. Dentzer received a grant of 13,166 shares of common stock on November 6, 2026, at a reported price of $0.845 per share. The shares were granted in lieu of cash for a portion of board fees. His directly held position following the grant was 34,197 shares, reflecting the shares held directly after the award.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.48%
Tags
insider
-
Rhea-AI Summary

Imunon, Inc. director Christine A. Pellizzari acquired 13,166 shares of Common Stock on November 6, 2026, as stock granted in lieu of cash for a portion of board fees. The reported price was $0.845 per share; she directly held 28,665 shares after the grant.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.48%
Tags
insider
Rhea-AI Summary

Imunon, Inc. director Frederick J. Fritz acquired 13 shares of common stock on November 6, 2026, as stock granted in lieu of cash for a portion of board fees. The award was reported at $0.8450 per share. His direct common-stock holdings following the transaction were 28,242 shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.48%
Tags
insider
-
Rhea-AI Summary

Imunon, Inc. reported that Chief Medical Officer Douglas Vincent Faller received a grant of 1,596 shares of common stock on November 6, 2026, bringing his directly held position to 76,356 shares. The transaction was reported at $0.845 per share. The remarks describe the stock as granted in lieu of cash for a portion of base salary.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.48%
Tags
insider
-
Rhea-AI Summary

Imunon, Inc. President and CEO Stacy Lindborg acquired 3,804 shares of common stock on November 6, 2026, as a grant in lieu of cash for a portion of base salary. The reported per-share amount was $0.845. After the award, she directly held 122,581 shares and held 778 shares indirectly through a 401(k) Plan.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.48%
Tags
insider
Rhea-AI Summary

Imunon, Inc. Executive Chairman of Board Michael H. Tardugno acquired 9,969 shares of common stock on November 6, 2026, as stock granted in lieu of cash for base salary. The transaction reported a per-share price of $0.8450. Tardugno's reported direct holdings afterward were 128,511 shares; a separate holding entry lists 4,622 shares held indirectly through an IRA.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.48%
Tags
insider

FAQ

How many Imunon (IMNN) SEC filings are available on StockTitan?

StockTitan tracks 116 SEC filings for Imunon (IMNN), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Imunon (IMNN)?

The most recent SEC filing for Imunon (IMNN) was filed on November 16, 2026.